378P Complement activation in colorectal cancer: Exploratory evaluation of C3aR as a prognostic biomarker

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths. Among patients with stage II and III disease, 20–30% experience recurrence within five years after tumor resection. Hence, a major challenge in clinical practice is the therapeutic stratification of these patients. The receptor for anaphylatoxin C3a (C3aR) is mainly expressed on the surface of myeloid cells. Under physiological conditions, the binding of C3a to C3aR contributes to innate immunity. Accumulating evidence reveals the controversial and context-dependent role of the complement system in the development and progression of several cancers, including CRC.